The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinasas as serum markers of bladder cancer;El papel de la metaloproteinasa de la matriz MMP-9 y del inhibidor tisular de metaloproteinasa TIMP-2 como marcadores séricos de cáncer vesical

Actas Urologicas Espanolas

Volumn 37, Issue 8, 2013, Pages 480-488

  Ramon De Fata F ^a   Ferruelo, A ^a   Andres G ^a   Gimbernat, H ^a   Sanchez Chapado M ^b   Angulo, J C ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Enzyme Linked ImmunoSorbent Assay; Metalloproteinase 2; Metalloproteinase 9; Tisular Inhibitor of Metalloproteinase 2

Indexed keywords

GELATINASE B; TIMP2 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; BLOOD; CASE CONTROL STUDY; ENSAYO POR INMUNOABSORCIÓN LIGADO A ENZIMAS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INHIBIDOR TISULAR DE METALOPROTEINASA-2; MALE; METALLOPROTEINASE-2; METALLOPROTEINASE-9; METALOPROTEINASA-2; METALOPROTEINASA-9; MIDDLE AGED; TISULAR INHIBITOR OF METALLOPROTEINASE-2; VERY ELDERLY;

ENSAYO POR INMUNOABSORCIÓN LIGADO A ENZIMAS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INHIBIDOR TISULAR DE METALOPROTEINASA-2; METALLOPROTEINASE-2; METALLOPROTEINASE-9; METALOPROTEINASA-2; METALOPROTEINASA-9; TISULAR INHIBITOR OF METALLOPROTEINASE-2;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84882919202     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2013.05.004     Document Type: Article

References (36)

1. J.C. Angulo, J.I. López, J.R. Larrinaga, and N. Flores Metastasising carcinoma of the urinary bladder presenting as a retro-orbital mass Scand J Urol Nephrol 25 1991 83 84
2. J.C. Angulo, J.I. López, N. Flores, and J.D. Toledo The value of tumor spread, grading and growth pattern as morphologic predictive parameters in bladder carcinoma. A revision of 1987 TNM Classification J Cancer Res Clin Oncol 119 1993 578 593
3. G. Andrés, N. Ashour, M. Sánchez-Chapado, S. Ropero, and J.C. Angulo El estudio de la metilación del ADN en el cáncer urológico: presente y futuro Actas Urol Esp 37 2013 368 375
4. S. Goodison, C.J. Rosser, and V. Urquidi Bladder cancer detection and monitoring: Assessment of urine- and blood-based marker tests Mol Diagn Ther 17 2013 71 84
5. O. Rodriguez-Faba, J. Palou-Redorta, J.M. Fernández-Gómez, F. Algaba, N. Eiró, and H. Villavicencio Matrix metalloproteinases and bladder cáncer: What is new? ISRN Urol 2012 2012 581539 10.5402/2012/581539
6. L.M. Coussens, B. Fingleton, and L.Y. Matrisian Matrix metalloproteinase inhibitors and cancer: Trials and tribulations Science 295 2002 2387 2392
7. L.J. McCawley, and L.M. Matrisian Matrix metalloproteinases: They're not just for matrix anymore! Curr Opin Cell Biol 13 2011 534 540
8. D.J. Grignon, W. Sakr, M. Toth, V. Ravery, J. Angulo, and F. Shamsa High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer Cancer Res 56 1996 1654 1659
9. K. Gohji, N. Fujimoto, A. Fujii, T. Komiyama, J. Okawa, and M. Nakajima Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection Cancer Res 56 1996 3196 3198
10. K. Gohji, N. Fujimoto, J. Ohkawa, A. Fujii, and M. Nakajima Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer Br J Cancer 77 1998 650 655
11. M.A. Moses, D. Wiederschain, K.R. Loughlin, D. Zurakowski, C.C. Lamb, and M.R. Freeman Increased incidence of matrix metalloproteinases in urine of cancer patients Cancer Res 58 1998 1395 1399
12. O. Rodríguez Faba, J.M. Fernández Gómez, J. Palou Redorta, S. Escaf Barmadah, F. Vizoso, and H. Villavicencio Mavrich Significance of collagenase 3 (matrix metalloproteinase 13) in invasive bladder cancer: Correlation with pathological parameters Urol Int 78 2007 140 144
13. C.A. Fernández, M.F. Wszolek, K.R. Loughlin, J.A. Libertino, I.C. Summerhayes, and A.P. Shuber A novel approach to using matrix metalloproteinases for bladder cancer J Urol 182 2009 2188 2194
14. J.C. Angulo, A. Ferruelo, J.M. Rodríguez-Barbero, C. Núñez, F. Ramón de Fata, and J. González Detección y estadificación molecular del cáncer vesical mediante RT-PCR a tiempo real para gelatinasas (MMP-2 MMP-9) y TIMP-2 en sangre periférica Actas Urol Esp 35 2011 127 136
15. D. Sbardella, G.F. Fasciglione, M. Gioia, C. Ciaccio, G.R. Tundo, and S. Marini Human matrix metalloproteinases: An ubiquitarian class of enzymes involved in several pathological processes Molecular Aspects of Medicine 33 2012 119 208
16. D. Bourboulia, and W.G. Stetler-Stevenson Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion Semin Cancer Biol 20 2010 161 168
17. E. Ozdemir, Y. Kakehi, H. Okuno, and O. Yoshida Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas J Urol 161 1999 1359 1363
18. G.C. Durkan, J.E. Nutt, C. Marsh, P.H. Rajjayabun, M.C. Robinson, and D.E. Neal Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer Clin Cancer Res 9 2003 2576 2582
19. K. Vasala, P. Pääkkö, and T. Turpeenniemi-Hujanen Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer Urology 62 2003 952 957
20. T. Sumi, H. Yoshida, Y. Hyun, T. Yasui, Y. Matsumoto, and K. Hattori Expression of matrix metalloproteinases in human transitional cell carcinoma of the urinary bladder Oncol Rep 10 2003 345 349
21. T. Szarvas, M. Becker, F.V. Dorp, C. Gethmann, M. Tötsch, and A. Bánkfalvi Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer Cancer Sci 101 2010 1300 1308
22. M.O. Grimm, O. Modlich, U. Brosius, K. Struse, H. Bojar, and T.A. Vogeli Expression and progression pattern of transitional cell carcinoma of the bladder J Urol 4 2000 557
23. B. Davies, J. Waxman, H. Wasan, P. Abel, G. Williams, and T. Krausz Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion Cancer Res 53 1993 5365 5369
24. F.J. Bianco, D.C. Gervasi, R. Tiguert, D.J. Grignon, J.E. Pontes, and J.D. Crissman Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade Clin Cancer Res 4 1998 3011 3016
25. K. Kanda, M. Takahasi, Y. Murakami, H. Kanayama, and S. Kagawa The role of the activated form of matrix-metalloproteinase-2 in urothelial cancer Br J Urol Int 86 2000 553 557
26. F. Monier, S. Mollier, M. Guillot, J.J. Rambeaud, F. Morel, and P. Zaoui Urinary release of 72 and 92 kDa Gelatinases, TIMP-2. N-GAL and conventional prognostic factors in urothelial carcinomas Eur Urol 42 2002 356 363
27. S. Eissa, R.A. Labib, S. Mourad, K. Kamel, and O. El-Ahmady Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer Eur Urol 44 2003 687 694
28. B. Offersen, M.M. Knap, M.R. Horsman, J. Verheijen, R. Hanemaaijer, and J. Overgaard Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival Acta Oncol 49 2010 1283 1287
29. S. Naruo, H. Kanayama, H. Takigawa, S. Kagawa, K. Yamashita, and T. Hayakawa Serum levels of a tissue inhibitor of metalloproteinase-1 (TIMP-1) in bladder cancer patients Int J Urol 1 1994 228 231
30. K. Guan, H. Ye, Z. Yan, Y. Wang, and S. Hou Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder Urology 61 2003 719 723
31. S. Stankovic, G. Konjevic, K. Gopcevic, V. Jovic, M. Inic, and V. Jurisic Activity of MMP-2 and MMP-9 in sera of breast cancer patients Pathol Res Pract 206 2010 241 247
32. S. Patel, G. Sumitra, B.C. Koner, and A. Saxena Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression Clin Biochem 44 2011 869 872
33. K. Vasala, and T. Turpeennniemi-Hujanen Serum tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 in complex with the inhibitor (MMP-2:TIMP-2) as prognostic markers in bladder cancer Clin Biochem 40 2007 640 644
34. J.I. López Comentario a: «Detección y estadificación molecular del cáncer vesical mediante RT-PCR a tiempo real para gelatinasas (MMP-2, MMP-9) y TIMP-2 en sangre periférica» Actas Urol Esp 35 2011 137
35. J.L. Beaudeux, P. Giral, E. Bruckert, M.J. Foglietti, and M.J. Chapman Matrix metalloproteinases, inflammation and atherosclerosis: Therapeutic perspectives Clin Chem Lab Med 42 2004 121 131
36. V. Masson, L.R. de la Ballina, C. Munaut, B. Wielockx, M. Jost, and C. Maillard Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes FASEB J 19 2005 234 236